Therapeutic Targeting of microRNAs in Cancer: Future Perspectives

Tutar, Lütfi; Tutar, Esen; Özgür, Aykut; Tutar, Yusuf

doi:10.1002/ddr.21273

Cited by 57 publications

(39 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiRNAs have emerged as an important kind of diagnostic, prognostic and predictive biomarker for different types of cancer, and earned a promising role for cancer biology (10,11). In addition, miRNAs offer potential new avenues for cancer treatment, for instance by using miRNA mimics or antogomirs (12,13). …”

Section: Introductionmentioning

confidence: 99%

dbDEMC 2.0: updated database of differentially expressed miRNAs in human cancers

et al. 2016

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are often deregulated in cancer and are thought to play an important role in cancer development. Large amount of differentially expressed miRNAs have been identified in various cancers by using high-throughput methods. It is therefore quite important to make a comprehensive collection of these miRNAs and to decipher their roles in oncogenesis and tumor progression. In 2010, we presented the first release of dbDEMC, representing a database for collection of differentially expressed miRNAs in human cancers obtained from microarray data. Here we describe an update of the database. dbDEMC 2.0 documents 209 expression profiling data sets across 36 cancer types and 73 subtypes, and a total of 2224 differentially expressed miRNAs were identified. An easy-to-use web interface was constructed that allows users to make a quick search of the differentially expressed miRNAs in certain cancer types. In addition, a new function of ‘meta-profiling’ was added to view differential expression events according to user-defined miRNAs and cancer types. We expect this database to continue to serve as a valuable source for cancer investigation and potential clinical application related to miRNAs. dbDEMC 2.0 is freely available at http://www.picb.ac.cn/dbDEMC.

show abstract

Section: Introductionmentioning

confidence: 99%

dbDEMC 2.0: updated database of differentially expressed miRNAs in human cancers

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Due to this one-to-many relationship, studying miRNA expression profiles could contribute more efficiently to construction of the molecular regulatory network as a whole, especially in characterizing cancer-associated regulation of molecular pathways or biological processes. miRNAs can be classified as either tumor suppressors or oncogenes (oncomirs) according to their expression profiles in cancer [8]. In breast cancer, at least 20 oncogenic miRNAs or cluster families have been identified to promote cell proliferation, invasion, migration, or angiogenesis [9].…”

Section: Introductionmentioning

confidence: 99%

Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis

Dingerdissen

Gupta

et al. 2018

Computers in Biology and Medicine

View full text Add to dashboard Cite

microRNAs (miRNAs) functioning in gene silencing have been associated with cancer progression. However, common abnormal miRNA expression patterns and their potential roles in cancer have not yet been evaluated. To account for individual differences between patients, we retrieved miRNA sequencing data for 575 patients with both tumor and adjacent nontumorous tissues from 14 cancer types from The Cancer Genome Atlas (TCGA). We then performed differential expression analysis using DESeq2 and edgeR. Results showed that cancer types can be grouped based on the distribution of miRNAs with different expression patterns between tumor and non-tumor samples. We found 81 significantly differentially expressed miRNAs (SDEmiRNAs) in a single cancer. We also found 21 key SDEmiRNAs (nine over-expressed and 12 under-expressed) associated with at least eight cancers each and enriched in more than 60% of patients per cancer, including four newly identified SDEmiRNAs (hsa-mir-4746, hsa-mir-3648, hsa-mir-3687, and hsa-mir-1269a). The downstream effects of these 21 SDEmiRNAs on cellular function were evaluated through enrichment and pathway analysis of 7,186 protein-coding gene targets mined from literature reports of differential expression of miRNAs in cancer. This analysis enables identification of SDEmiRNA functional similarity in cell proliferation control across a wide range of cancers, and assembly of common regulatory networks over cancer-related pathways. These findings were validated by construction of a regulatory network in the PI3K pathway. This study provides evidence for the value of further analysis of SDEmiRNAs as potential biomarkers and therapeutic targets for cancer diagnosis and treatment.

show abstract

“…An increasing number of studies have suggested that miRNAs perform a crucial role in regulating cancer cells by acting as oncogenes or tumor suppressers (9)(10)(11). Therefore, miRNAs may serve as potential biomarkers and targets for the diagnosis and treatment of various types of cancer (12).…”

Section: Introductionmentioning

confidence: 99%

miRNA-34a enhances the sensitivity of gastric cancer cells to treatment with paclitaxel by targeting E2F5

Zhao

2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Gastric cancer (GC) is one of the most common types of malignant cancer worldwide, however improvements are required to the current therapies for GC. Although paclitaxel is one of the most promising chemotherapeutic agents in clinical use for GC, the resistance to paclitaxel that develops during treatment is a major obstacle to further treatments of GC. The present study reports that micro (mi) RNA-34a, a tumor suppressor in various types of cancer, may be an important regulator of chemoresistance in GC, as miRNA-34a mimics and inhibitors, enhance and inhibit the chemotherapeutic efficacy of paclitaxel, respectively. In addition, the present study identified that E2F transcription factor 5 (E2F5), a key oncogenic protein, is the direct target candidate of miRNA-34a. Previous studies have demonstrated that the inhibition of E2F5 by specific E2F5 small interfering RNA also increases the sensitivity of GC cells to paclitaxel. In conclusion, the present data suggest that miRNA-34a enhances the treatment of sensitive GC cells to paclitaxel by targeting E2F5. Therefore, the miRNA-34a/E2F5 axis appears to be a potential promising therapeutic target for overcoming the chemotherapeutic resistance of GC.

show abstract

Therapeutic Targeting of microRNAs in Cancer: Future Perspectives

Cited by 57 publications

References 97 publications

dbDEMC 2.0: updated database of differentially expressed miRNAs in human cancers

dbDEMC 2.0: updated database of differentially expressed miRNAs in human cancers

Identification of key differentially expressed MicroRNAs in cancer patients through pan-cancer analysis

miRNA-34a enhances the sensitivity of gastric cancer cells to treatment with paclitaxel by targeting E2F5

Contact Info

Product

Resources

About